Latest Breaking News On - Miguel saps - Page 1 : comparemela.com

Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation

– Newly published data highlights additional efficacy endpoints from trial – – Linaclotide is the first and only FDA-approved prescription therapy for children and adolescents aged 6-17 years.

United statesGeorgee batchelorIronwood pharmaceuticals nasdaqJerome foundationUniversity of miami health systemUniversity of miamiIronwood pharmaceuticals incNational population projection tablesDrug administrationDivision of pediatric gastroenterologyIronwood pharmaceuticalsLancet gastroenterologyMiguel sapsPediatric gastroenterologyEndowed chairMiami health

Ironwood Pharma (IRWD) Reports Publication of New Linaclotide Phase III Data

Ironwood Pharma (IRWD) Reports Publication of New Linaclotide Phase III Data
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesGeorgee batchelorDivision of pediatric gastroenterologyUniversity of miami health systemIronwood pharmaceuticals inc nasdaqUniversity of miamiDrug administrationIronwood pharmaceuticalsLancet gastroenterologyMiguel sapsPediatric gastroenterologyEndowed chairMiami health

New Phase 3 Data Reinforces Safety, Efficacy of Linaclotide for Pediatric Functional Constipation

The new data was published in The Lancet Gastroenterology & Hepatology and highlighted additional efficacy endpoints from the study used to support linaclotide’s FDA approval in 2023.

Georgee batchelorMichael shetzlineDrug administrationUniversity of miamiIronwood pharmaceuticals announcesIronwood pharmaceuticalsUniversity of miami health system miguel sapsMiami health systemMiguel sapsLancet gastroenterologyEndowed chairBristol stool form scaleIronwood announces publicationNew linaclotide phaseAdolescents agedNew indication

Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

– Pivotal Phase III data will be spotlighted via an oral presentation – – Additional efficacy and safety data will be featured across four posters – . | June 18, 2023

United statesNew yorkHong kongUniversity of miamiTime toJeffrey samuel hyamsAstra zenecaJulie khlevnerSamuel nurkoConnecticut children medical centerIronwood pharmaceuticalsDrug administrationIronwood pharmaceuticals incIronwood pharmaceuticals nasdaqJerome foundationDisease week